This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-24. Anything still debated is marked as such rather than presented as settled.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Artistic Achievement – Lumino City Audio Achievement – Alien: Isolation Best Game – Destiny British Game – Monument Valley Debut Game – Never Alone Family – Minecraft: Console Editions Game Design – Middle-earth: Shadow of Mordor Game Innovation – The Vanishing of Ethan Carter Mobile & Handheld – Monument Valley Online Multiplayer – Hearthstone: Heroes of Warcraft Original Music – Far Cry 4 Original Property – Valiant Hearts: The Great War Performer – Ashley Johnson (as Ellie, The Last of Us: Left Behind) Persistent Game – League of Legends Sports – OlliOlli Story – The Last of Us: Left Behind BAFTA Ones to Watch Award – Chambara Academy Fellowship – David Braben
==== Cross-linking and phosphorylation ==== Allergen-mediated FcεR1 cross-linking signals are very similar to the signaling event resulting in antigen binding to lymphocytes. The Lyn tyrosine kinase is associated with the cytoplasmic end of the FcεR1 β chain. The antigen cross-links the FcεR1 molecules, and Lyn tyrosine kinase phosphorylates the ITAMs in the FcεR1 β and γ chain in the cytoplasm. Upon the phosphorylation, the Syk tyrosine kinase gets recruited to the ITAMs located on the γ chains. This causes activation of the Syk tyrosine kinase, causing it to phosphorylate. Syk functions as a signal amplifying kinase activity due to the fact that it targets multiple proteins and causes their activation. This antigen stimulated phosphorylation causes the activation of other proteins in the FcεR1-mediated signaling cascade.
=== Overdose === Signs of overdose range through mental confusion, dysarthria, paradoxical reactions, drowsiness, hypotonia, ataxia, hypotension, hypnotic state, coma, cardiovascular depression, respiratory depression, and death. Fatal overdoses on benzodiazepines alone are rare and less common than with barbiturates. Early management of people under alert includes emetics, gastric lavage, and activated charcoal. Otherwise, management is by observation, including vital signs, support and, if necessary, giving intravenous flumazenil.
In May 2022, Grand Commander Viñas Alonso was prevented by the State Security Unit from traveling on official business to the United States to attend several Freemasonic and Masonic events, including the Summit of the Americas in Los Angeles. The State Security Unit continued their campaign to remove Viñas Alonso from power, and began communicating with the Supreme Court of Masonic Justice to launch an investigation into his "misconduct," and to strip him of his Masonic rights. On May 20, 2022, the Grand Lodge of Cuba hosted a centenary celebration of the 1902 Proclamation of the Republic of Cuba. In September, 2022, the High Chamber of the Supreme Court of Masonic Justice approved a letter to be delivered to President Díaz-Canel officially requesting that May 20 be observed as a national holiday, despite Díaz-Canel's past public rejection of the May 20th movement. Sometime later in 2022, Alfonso Vidal was approached by members of the State Security Unit to give evidence against Viñas Alonso, and to participate in the official expulsion of the Grand Commander from Freemasonry. State Security Unit agents took him to an office in Havana and attempted to cultivate him as an agent of the state. One agent in particular, who went by the codename Agente Poll, told him that his office had been assigned to monitor Freemasonry in Cuba for over 40 years, and had agents placed in Lodges all over Cuba.
Sources: en.wikipedia.org
==== Mechanism of action ==== Dronabinol partially stimulates both the cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2), with a stronger stimulatory effect observed in the former. Dronabinol prevents nausea and vomiting and stimulates appetite by directly acting on the CB1 receptors in the vomiting and appetite control centres in the brain.
=== October === 1 October – John Braggins, botanist and bryologist (University of Auckland, Auckland War Memorial Museum) (born 1944). 2 October – Mac Gardner, clinical geneticist (University of Otago, University of Melbourne) (born 1942). 4 October – Gordon Keys, atmospheric scientist (DSIR, NIWA), Royal Society of New Zealand Science and Technology Silver Medal (1995) (born 1930). 6 October – Margaret, Lady Liley, paediatrician, general practitioner and farmer (born 1928). 7 October – Graham Bell, police officer and television presenter (Police Ten 7) (born 1946). 8 October – Wally Yovich, businessman, local politician and philanthropist, Whangārei District Councillor (1989–1995) (born 1939). 9 October – Cliff Tait, aviator, politician and writer, Hamilton City Councillor (1992–1995) (born 1929). 10 October – Roger Harris, cricketer (Auckland, national team) (born 1933). 11 October – Richard Nottage, diplomat and public servant, ambassador to Indonesia (1980–1982) and Japan (1987–1988), permanent representative to the UN in Geneva (1984–1987), Secretary of Foreign Affairs and Trade (1991–1999) (born 1939). 15 October – Jim Bolger, politician, MP for King Country (1975–1996) and Taranaki-King Country (1996–1998), Minister of Labour (1978–1984), leader of the National Party (1986–1997), Prime Minister (1990–1997), Ambassador to the United States (1998–2002), chancellor of the University of Waikato (2007–2019), Privy Counsellor (since 1991), Member of the Order of New Zealand (since 1997) (born 1935). 20 October – So You Think, Hall of Fame Thoroughbred racehorse, W. S.
== Further reading == E. M. Thurman, M. S. Mills, Solid-Phase Extraction: Principles and Practice, Wiley-Interscience, 1998, ISBN 978-0-471-61422-7 Nigel J.K. Simpson, Solid-Phase Extraction: Principles, Techniques, and Applications, CRC, 2000, ISBN 978-0-8247-0021-8 James S. Fritz, Analytical Solid-Phase Extraction, Wiley-VCH, 1999, ISBN 978-0-471-24667-1
=== Optimal solution === The optimal "threading" of a protein sequence onto a known structure and the production of an optimal multiple sequence alignment have been shown to be NP-complete. However, this does not imply that the structural alignment problem is NP-complete. Strictly speaking, an optimal solution to the protein structure alignment problem is only known for certain protein structure similarity measures, such as the measures used in protein structure prediction experiments, GDT_TS and MaxSub. These measures can be rigorously optimized using an algorithm capable of maximizing the number of atoms in two proteins that can be superimposed under a predefined distance cutoff. Unfortunately, the algorithm for optimal solution is not practical, since its running time depends not only on the lengths but also on the intrinsic geometry of input proteins.
=== Prehypertension === In a four-year randomized controlled trial, candesartan was compared to placebo to see whether it could prevent or postpone the development of full-blown hypertension in people with so-called prehypertension. During the first two years of the trial, half of participants were given candesartan while the other half received placebo; candesartan reduced the risk of developing hypertension by nearly two-thirds during this period. In the last two years of the study, all participants were switched to placebo. By the end of the study, candesartan had significantly reduced the risk of hypertension, by more than 15%. Serious adverse effects were more common among participants receiving placebo than in those given candesartan.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.